---
document_datetime: 2025-10-15 14:02:57
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: qinlock-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3670088
conversion_datetime: 2025-12-28 09:08:58.268591
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## QINLOCK

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.I ACTIVE SUBSTANCE - B.I.z Other | 07/10/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296456                     | variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000296131 | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/10/2025 | N/A |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Variation type II / EMA/VR/0000284381 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: C.I.4: Update of section 4.5 of the SmPC based on results from drug-drug interaction study DCC-2618-01-007. In addition, the MAH took the opportunity to implement editorial changes to the PI, as well as, to update the list of representatives in the Packagae | 11/09/2025 |     | SmPC and PL | SmPC new text Section 4.5: Interaction with other medicinal products and other forms of interaction CYP isoform-selective substrates Ripretinib is a weak inhibitor of CYP2C8. Co-administration of QINLOCK with repaglinide (a sensitive index substrate for CYP2C8) increased repaglinide AUC0- âˆž by 26%. Repaglinide Cmax was unchanged; therefore, dose adjustment is not required. UGT1A substrates In vitro studies suggested that ripretinib is an inhibitor of UGT1A1, UGT1A3, UGT1A4, UGT1A7, and UGT1A8. QINLOCK is to be used with caution in combination with clinical substrates of UGT1A enzymes (e.g. bictegravir, cabotegravir, dolutegravir, raltegravir, lamotrigine), as co- administration may lead to increased exposure of these substrates. Clinical studies with UGT1A substrates have not been conducted. Section 4.8: The frequency of Grade 3 decreased left ventricular ejection fraction in the pooled safety population was corrected to 2 % (previously 4 %). For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                       | SmPC based on results from in vitro study DCC-2618-03-0046 to investigate the interaction between QINLOCK and UGT1A substrates.                                                                                                                                                                                                                                                                                                                                             |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000278855 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - to provide an updated Environmental Risk Assessment report.                                                                                                                                                                                                                                                                                                                          | 08/08/2025 | N/A |
| Variation type IA / EMA/VR/0000286650 | This was an application for a group of variations. B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted B.III.2.a Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.a.2 Excipient/active substance starting material - Accepted | 17/07/2025 | N/A |
| Variation type IB / EMA/VR/0000271896 | B.I.a.4 Change to in-process tests or limits applied during the manufacture of the active substance - B.I.a.4.c Deletion of a non- significant in-process test - Accepted                                                                                                                                                                                                                                                                                                   | 23/05/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000261098   | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted   | 28/03/2025   | N/A   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|